drugset / Trial / NCT01325298

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

NCT01325298

Phase 2 Unknown 250 enrolled Mercy Center for Corrective Eye Surgery
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate two different ultraviolet (UV) dosing regimens for corneal collagen cross linking to slow the progressive changes in corneal curvature in eyes with progressive keratoconus or post-refractive surgery ectasia.

Timeline

Start
2011-03
Primary completion
2014-03
Completion
2014-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Riboflavin Other / unclassified 0.1 % Topical